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The serine/threonine kinase Akt/PKB is a potent reg-
ulator of cell survival and has oncogenic transformation
potential. Previously, it has been shown that Akt can
activate the transcription factor NF-kB and that this
functions to block apoptosis induced by certain stimuli.
The mechanism whereby Akt activates NF-kB has been
controversial, with evidence supporting induction of
nuclear translocation of NF-kB via activation of IkB ki-
nase activity and/or the stimulation of the transcription
function of NF-kB. Here we demonstrate that Akt targets
the transactivation function of NF-kB by stimulating the
transactivation domain of RelA/p65 in a manner that is
dependent on IkB kinase b activity and on the mitogen-
activated protein kinase p38 (p38). Activation of RelA/
p65 transactivation function requires serines 529 and
536, sites shown previously to be inducibly phosphoryl-
ated. Consistent with the requirement of p38 in the ac-
tivation of NF-kB transcriptional function, expression of
activated Akt induces p38 activity. Furthermore, the
ability of IL-1b to activate NF-kB is known to involve
Akt, and we show here that IL-1b induces p38 activity in
manner dependent on Akt and IkB kinase activation.
Interestingly, activated Akt and the transcriptional co-
activators CBP/p300 synergize in the activation of the
RelA/p65 transactivation domain, and this synergy is
blocked by p38 inhibitors. These studies demonstrate
that Akt, functioning through IkB kinase and p38, in-
duces the transcription function of NF-kB by stimulat-
ing the RelA/p65 transactivation subunit of NF-kB.
Akt/PKB is a serine/threonine kinase that is activated in
response to certain growth factors and cytokines (1, 2). Con-
sistent with its activation by growth factors, Akt has trans-
forming potential (3). Akt isoforms have been shown to be
overexpressed in breast cancer cell lines, in ovarian and pan-
creatic cancers, and amplified in gastric adenoma (4, 5). Addi-
tionally, Akt is a downstream activator for oncogenic Ras and
Src and for the proto-oncoprotein HER-2/neu (6–8). Impor-
tantly, Akt provides a potent cell survival signal that is likely
involved in its transformation and growth-promoting proper-
ties (3). Mechanisms associated with the ability of Akt to sup-
press apoptosis include the phosphorylation and inactivation of
many proapoptotic proteins (9–15). Additionally, Akt has been
shown to activate the transcription factor NF-kB to provide cell
survival functions (7, 16–19).
Classic nuclear factor-kB (NF-kB) is a heterodimer composed
of the p50 and the RelA/p65 subunits. NF-kB is activated by a
variety of stimuli including cytokines and oncoproteins (20, 21).
In unstimulated cells, the majority of NF-kB is found in the
cytoplasm associated with a family of inhibitory molecules
known as the IkBs. The canonical NF-kB activation mechanism
involves the phosphorylation of IkB on two critical serine res-
idues by the IkB kinase (IKK)1 signalsome complex (22–25).
Phosphorylated IkB is then targeted for ubiquitination and
subsequent degradation by the 26 S proteosome, which allows
liberated NF-kB to translocate to the nucleus, where it acti-
vates transcription of NF-kB-responsive genes (20, 21).
Although the induced nuclear translocation of NF-kB has
been highly regarded as the principal method to activate NF-
kB-dependent gene expression, an alternate mechanism of
NF-kB activation is emerging that involves the phosphoryla-
tion of the RelA/p65 transactivation subunit. For example, it
has been shown that the proinflammatory cytokines tumor
necrosis factor and IL-1b lead to the phosphorylation of RelA/
p65 and the subsequent stimulation of NF-kB transactivation
through pathways distinct from induced nuclear translocation
(18, 26, 27). The catalytic subunit of protein kinase A (PKAc)
has also been shown to phosphorylate RelA/p65, which leads to
the association of RelA/p65 with the CREB-binding protein/
p300 (CBP/p300) transcriptional co-activator (28, 29). Recently,
the generation of GSK3 and T2K (TBK1) knockout mice has
highlighted the physiological importance of modulating trans-
activation functions of NF-kB, because cells generated from
these animals are capable of inducing NF-kB nuclear translo-
cation but are deficient in their ability to stimulate transacti-
vation functions of NF-kB (30, 31). In addition, evidence has
been presented that the stress-activated kinase p38 is involved
in the regulation of NF-kB transcription function at a level
distinct from the induction of nuclear translocation (32, 33).
These studies indicate that dual controls exist for NF-kB with
mechanisms controlling induction of nuclear translocation of
NF-kB as well as regulating the inherent transcriptional activ-
ity of NF-kB.
Reports describing processes whereby Akt stimulates NF-kB
activity have indicated different mechanisms whereby this
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process may occur. Two studies indicated that Akt, either in the
context of tumor necrosis factor signaling or in response to
growth factor stimulation, stimulated NF-kB nuclear translo-
cation via the activation of the IKK complex (16, 17). Another
study indicated that Akt alone could not induce nuclear trans-
location of NF-kB but synergized with PMA to induce this
response (19). Arguments against the involvement of Akt in
controlling nuclear accumulation of NF-kB have been recently
reported (34). Others, including ourselves, have provided evi-
dence that Akt signaling involves the stimulation of the tran-
scription function of NF-kB (7, 18). Thus, we showed that the
ability of oncogenic Ras to activate NF-kB transcriptional ac-
tivity is dependent on Akt activity (7). In a separate study,
Sizemore et al. showed that IL-1b induces phosphorylation of the
RelA/p65 subunit in an Akt-dependent manner and that IL-1b
activated the RelA/p65 transcriptional activation domain (18).
In this study, we show that the ability of Akt to stimulate the
transactivation potential of the RelA/p65 subunit of NF-kB
requires IKK and p38. Expression of activated Akt in IKKb
null mouse embryo fibroblasts (MEFs) significantly reduces
transcriptional activity of NF-kB. In addition, mutation of ser-
ine 529 and the IKKb phosphorylation site serine 536 (24, 35,
36) within the RelA/p65 transactivation domain, sites previ-
ously shown to be inducibly phosphorylated, decreases the ac-
tivation of NF-kB-mediated transcription in response to Akt.
Since p38 has been determined to activate NF-kB by targeting
the transactivation function of NF-kB, we examined the role of
p38 in Akt-mediated NF-kB transactivation. Treatment of cells
with IL-1b or expression of an activated form of Akt stimulates
the phosphorylation and activation of p38. Interestingly, IL-
1b-induced phosphorylation of p38 requires Akt and IKK. Fur-
thermore, inhibition of p38 kinase activity by the p38 inhibitor
SB203580 significantly reduces Akt- and IL-1b-induced NF-kB
activation. The stimulation of the RelA/p65 transactivation
domain is most likely not due to a direct phosphorylation event
on RelA/p65 by p38 (32); rather, we provide evidence that p38
activates RelA/p65 in response to Akt through cooperation with
the CBP/p300 transcriptional co-activator. These studies define
new mechanisms for Akt-mediated NF-kB transactivation and
demonstrate that Akt utilizes IKK and the p38 MAPK to stim-
ulate the transactivation potential of the RelA/p65 subunit of
NF-kB.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Murine NIH 3T3 fibroblasts were grown
in Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.) supple-
mented with 10% calf serum (Hyclone Laboratories, Logan, UT) and
penicillin/streptomycin unless otherwise indicated. Human 293T kid-
ney cells and IKK null mouse embryo fibroblasts were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (Hyclone Laboratories, Logan, UT) and penicillin/streptomycin
unless otherwise indicated. The specific p38 MAPK pharmacological
inhibitor SB203580 and the MEK inhibitor PD98059 (Calbiochem) were
used at a working concentration of 600 nM and 2 mM, respectively,
unless otherwise indicated. Recombinant human IL-1b (Promega Corp.,
Madison, WI) or recombinant mouse IL-1b (Life Technologies) was used
at a concentration of 5 ng/ml.
Plasmid Constructs and Mutagenesis—3x-kB luciferase reporter con-
structs contain 4 kB DNA binding consensus sites from the MHC class
I promoter fused upstream to firefly luciferase. The Gal4 luciferase
constructs (Gal4-Luc) contain five Gal4 DNA consensus binding sites
derived from the yeast GAL4 gene upstream of luciferase, and Gal4-p65
constructs have the yeast Gal4 DNA binding domain fused to the
carboxyl-terminal transactivation domain of p65 (37). Activated Akt as
well as dominant negative constructs have been described previously
(38, 39). Wild type, dominant negative p38, MAPK kinase 6 (MKK6),
and IKK constructs have been described previously (25, 40). Mutagen-
esis was performed per the manufacturer’s suggestions (Stratagene, La
Jolla, CA). Briefly, oligonucleotides were made corresponding to the
sequence in RelA/p65 overlapping the serines 529 and 536. PCR was
performed, and products were digested with DpnI and subsequently
transformed into the XL-1 Blue strain of Escherichia coli. All mutants
were verified by sequencing.
Transfection and Luciferase Reporter Assays—NIH3T3 cells at 60–
80% confluency were transiently transfected using the Superfect rea-
gent (Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. Briefly, plasmid constructs (1–2 mg of DNA total) were diluted in
serum-free medium and mixed with the Superfect reagent. Complexes
were allowed to form for 10 min before serum-containing medium was
added to the mixture. The cells were washed once with 13 phosphate-
buffered saline, and Superfect-DNA complexes were added to the cells
and placed in a humidified incubator at 37 °C with 5% CO2. Three hours
after the addition, cells were washed with 13 phosphate-buffered saline
and replenished with fresh serum-containing medium. Human 293T
cells at 70–80% confluency were transfected by the calcium phosphate
protocol. 24–48 h post-transfection, cells were washed once with 13
phosphate-buffered saline and lysed in Reporter Lysis Buffer (Promega,
Madison, WI) for 10 min at room temperature. Extracts were collected
and cleared by centrifugation at high speed. Protein concentration was
determined with the Bio-Rad protein assay dye reagent. D-Luciferin
was used as a substrate, and relative light units were measured using
an AutoLumat LB953 luminometer (Berthold Analytical Instruments).
Results were normalized to an internal b-galactosidase-expressing
plasmid (PCMV-LacZ) by a b-galactosidase colorimetric assay followed
by spectrophotometric quantitation (Promega, Madison, WI). In addi-
tion, cells transfected with Akt, p38, or IKK mutant constructs were
co-transfected with pCMV-LacZ and assayed for transfection efficiency
and/or cell death by counting b-galactosidase-positive cells as previ-
ously described (41).
Western Blot Analysis and Kinase Assays—Western blot analysis was
performed by preparing whole cell extracts in the presence of protease
inhibitors or by lysing cells in 23 SDS sample buffer. The indicated
primary antibodies were incubated, washed, and visualized by incuba-
tion with horseradish peroxidase-conjugated secondary antibodies (Pro-
mega, Madison, WI) and ECL chemiluminescent reagents (Amersham
Pharmacia Biotech). Western blotting antibodies were obtained from
the following companies: Akt and p38 antibodies (New England Biolabs,
Beverly, MA); M2 FLAG epitope and a-tubulin antibodies (Sigma), and
HA epitope antibody (Babco, Berkeley, CA). The p38 kinase assays were
performed as per the manufacturer’s instructions (Cell Signaling Tech-
nology, Inc., Beverly, MA).
RESULTS
Akt Stimulates the Transactivation Domain I of RelA/p65 by
Utilizing the IkB Kinase b—Various cellular stimuli can acti-
vate NF-kB-dependent transcription, at least in part, through
mechanisms independent of signaling pathways that influence
nuclear translocation. These signaling pathways stimulate the
transactivation domain of the RelA/p65 subunit of NF-kB, pre-
sumably by targeting basal or induced levels of NF-kB in the
nucleus (7, 26). Previous work in our laboratory has established
that Akt activates NF-kB by stimulating the carboxyl-terminal
transactivation domain I of RelA/p65. In addition, expression of
a dominant negative mutant of IKKb inhibited the ability of
Akt to activate NF-kB (7). Our results imply that Akt requires
IKK to efficiently stimulate the transactivation function of
NF-kB. To further address this question, we were interested in
determining if Akt could activate NF-kB-dependent transcrip-
tion in a setting where endogenous IKK is absent. The multi-
subunit IKK complex contains two primary catalytic subunits,
IKKa and IKKb, and each has been shown to be involved in
NF-kB activation at the level of nuclear accumulation (20). We
utilized nullizygous IKKa and IKKb mouse embryo fibroblasts
(MEFs) and performed transient transfection experiments with
M-Akt or full-length wild type RelA/p65 and an NF-kB reporter
construct (3X-kB Luc). As seen in Fig. 1A, wild type RelA/p65
activated the NF-kB-responsive promoter equally in the wild
type, IKKa2/2, or IKKb2/2 cells as expected. However, in
response to activated Akt, the IKKb2/2 cells were deficient in
NF-kB-dependent transcriptional activation, and, furthermore,
reintroduction of IKKb by transfection restored this activity.
Consistent with the role of Akt in regulating NF-kB transcrip-
tional activity, IKKb2/2 cells were inhibited in their ability to
activate a Gal4-dependent luciferase reporter when transfected
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with activated Akt and a fusion (Gal4-p65) between the Gal4
DNA binding domain and the transactivation domain I of RelA/
p65 (data not shown). To determine if the reduction of NF-kB
activity was due to aberrant expression of these proteins, the
extracts were reanalyzed for M-Akt, IKKa, and IKKb expres-
sion by Western blot, and both the IKKa2/2 and IKKb2/2
MEFs show equal levels of M-Akt protein (data not shown).
This result demonstrates that Akt requires endogenous IKKb for
efficient stimulation of NF-kB-dependent transcription in a man-
ner distinct from the induction of nuclear translocation of NF-kB.
Since Akt expression alone does not induce nuclear localiza-
tion of NF-kB and because Akt requires IKK for activation of
NF-kB (7, 16, 17, 19), we were interested in determining
whether IKK utilizes a specific site in RelA/p65 for Akt-medi-
ated stimulation of RelA/p65. Since IKKb has been reported to
phosphorylate RelA/p65 on serine 536 in vitro and in vivo, it
was important to determine if this site is essential for Akt-
mediated RelA/p65 transactivation (24, 36). To address this
question, we utilized a plasmid encoding the Gal4-p65 fusion
protein, where sequences encoding the DNA-binding domain of
Gal4 have been joined with sequences encoding the transacti-
vation domain of RelA/p65 (37). This plasmid, when co-trans-
fected with a Gal4-Luc reporter, allows us to determine
whether cellular signals up-regulate gene expression by specif-
ically targeting the transactivation domain of the RelA/p65
subunit of NF-kB. To examine the importance of the reported
IKKb phosphorylation site, Gal4-p65 was mutated at serine
536 and for control purposes at serine 529 (Gal4-p65 S536A
and S529A). The Gal4-p65 S529A mutant was examined, be-
cause serine 529 has been previously shown to be important for
transactivation of NF-kB in response to tumor necrosis factor
(26). NIH 3T3 cells were transiently co-transfected with Gal4-
Luc, wild type Gal4-p65, Gal4-p65 S529A, or Gal4-p65 S536A
in the presence (M-Akt) or absence (VC) of activated Akt. As
shown in Fig. 1B, M-Akt stimulates the transactivation func-
tion of RelA/p65 but has little or no effect on gene expression
when serine 529 or serine 536 are mutated to alanine. In
addition, stimulation of cells with IL-1b also required serines
529 and 536 for efficient activation of NF-kB transactivation
function (data not shown). These results demonstrate that a
known IKKb phosphorylation site, serine 536, and a known
tumor necrosis factor-inducible site, serine 529, are each re-
quired for Akt to efficiently stimulate the transactivation do-
main of the RelA/p65 subunit of NF-kB.
IL-1b Requires Akt and IKK for Efficient Stimulation of p38
Activity—Previous data from our laboratory and from others
have suggested that the stress-activated kinase p38 is required
for activation of NF-kB by expression of oncogenic Ras or by
IL-1b treatment (33, 42). Additionally, p38 and IL-1b have
been shown to modulate the transactivation potential of NF-kB
independent of signals that induce nuclear accumulation and
DNA binding (18, 33, 43). Therefore, we were interested in
determining if p38 was required by IL-1b and Akt to modulate
the transactivation potential of NF-kB, since it has also been
demonstrated that Akt modulates the transactivation func-
tions of NF-kB (7, 18). First, it was important to determine if
Akt can stimulate the phosphorylation of p38 and therefore
lead to its activation. To address this question, FLAG-tagged
wild type p38 (FLAG-p38) and activated Akt were transiently
transfected into human 293T cells. 48 h post-transfection, ex-
tracts were prepared and analyzed for the presence of phospho-
rylated p38 using a p38 phosphospecific antibody. As shown in
Fig. 2A, activated Akt induces the phosphorylation of FLAG-
p38, suggesting that p38 is a downstream target of Akt signal-
ing. The activity of p38 in response to M-Akt was also meas-
ured by p38 kinase assay, and, as shown in Fig. 2A, M-Akt
stimulated the activity of p38 to phosphorylate the transcrip-
tion factor ATF-2, a known p38 substrate. These extracts were
also analyzed for equivalent FLAG-p38 and a-tubulin (to con-
trol for loading) expression (Fig. 2A, bottom panels). Interest-
ingly, IL-1b has been shown to activate both Akt and p38;
however, it has not been demonstrated that p38 is a target of
IL-1b-Akt signaling (18, 44). Fig. 2B demonstrates that stim-
ulation of cells with IL-1b leads to the activation of p38 as
previously reported (44). Interestingly, this activation requires
functional Akt because concomitant expression of a dominant
FIG. 1. Akt-mediated NF-kB activation requires IKKb and ser-
ine 536 of RelA/p65. A, wild type, IKKa, and IKKb nullizygous mouse
embryo fibroblasts were transfected with 3X-kB luciferase, vector con-
trol, M-Akt (2 mg each), p65 (100 ng), or wild type IKKa and IKKb (for
reintroduction experiments). B, NIH 3T3 cells were transiently co-
transfected with Gal4-Luc, Gal4-p65 mutants S529A and S536A (100
ng each), and activated myristylated Akt (M-Akt) or a vector control
plasmid (VC) (2 mg each). 48 h post-transfection, luciferase levels were
assayed, normalized, and expressed as -fold induction over the vector
control 6 S.D. of three independent experiments.
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negative mutant of Akt (DN-Akt) effectively abolished the abil-
ity of IL-1b to activate p38. To control for equivalent expression
of FLAG-p38 and DN-Akt, we reanalyzed these extracts with
FLAG- and HA-specific antibodies, respectively (Fig. 2B, bot-
tom panels). Taken as a whole, these results suggest that Akt
signals to activate p38 and that IL-1b requires Akt for efficient
stimulation of p38.
Since IKKb is required for Akt-mediated NF-kB activity (Fig.
1A), we were also interested in determining if IL-1b stimula-
tion of p38 required the IKK pathway. To address this ques-
tion, 293T cells were transiently transfected with constructs
encoding a vector control plasmid (VC), FLAG-p38, dominant
negative MKK6 (DN-MKK6), and FLAG-tagged dominant neg-
ative IKKb (F-DN-IKKb (SS-AA)). The dominant negative
IKKb construct affects both endogenous IKKa and IKKb func-
tion, because the dominant negative IKKb dimerizes with and
inactivates both IKK subunits (23). 24 h post-transfection, the
cells were stimulated with IL-1b for 30 min and assayed for p38
phosphorylation status. As shown in Fig. 2C, DN-MKK6
blocked the ability of IL-1b to stimulate p38 phosphorylation,
as expected (lane 4). Interestingly, expression of DN-IKKb also
blocked IL-1b-mediated stimulation of p38 phosphorylation
(lane 5). In addition, Western analysis was performed to control
for proper expression of the transfected constructs and equal
loading (Fig. 2C, bottom panels). However, these results do not
distinguish between the IKK subunits relative to which one
may be required for this process. To address this question, we
performed similar experiments utilizing the IKKa and IKKb
null MEFs. These cells were treated with IL-1b for 30 min and
assayed for phosphorylated endogenous p38 as described
above. As shown in Fig. 2D, cells expressing wild type IKKa
and IKKb (WT) and cells lacking the IKKb subunit (IKKb2/2)
retain the ability of IL-1b to stimulate phosphorylation of p38
(lanes 1 and 2 and lanes 5 and 6), but interestingly, the IKKa
null MEFs are defective in IL-1b-mediated p38 phosphoryla-
tion (lanes 3 and 4). This observation suggests that IL-1b
signaling requires IKKa, but not IKKb, for stimulation of p38
and potentially places p38 downstream of the IL-1b-Akt-IKK
pathway (see “Discussion”).
IL-1b and Akt Utilize the Mitogen-activated Protein Kinase
p38 for Transactivation of NF-kB—To test whether p38 medi-
ates the stimulation of NF-kB transcriptional activity by Akt
and IL-1b, we suppressed p38 activity in cells expressing M-
Akt and determined the effect on NF-kB transactivation.
NIH3T3 cells were co-transfected with plasmids encoding M-
Akt, Gal4-Luc, and Gal4-p65 and then were treated with the
FIG. 2. IL-1b requires Akt and IKK for efficient stimulation of p38 activity. A, human 293T cells were transiently transfected with
constructs encoding VC, M-Akt, or FLAG-tagged p38 (FLAG-p38) (2 mg each). 48 h post-transfection whole cell extracts were isolated and assayed
for phosphorylated p38 using a phosphospecific p38 antibody or p38 kinase activity by assaying phosphorylated ATF-2. Extracts were reanalyzed
for equivalent expression of FLAG-p38 and a-tubulin for control purposes. NS, nonspecific bands. B, 293T cells were transfected with constructs
encoding FLAG-p38 and/or a dominant negative Akt mutant, Akt K179A (HA-DN-Akt) (2 mg each). 48 h post-transfection, cells were stimulated
with recombinant human IL-1b (5 ng/ml) for 30 min and assayed for p38 phosphorylation status. Extracts were reanalyzed for expression of
FLAG-p38 and HA-DN-Akt (NS indicates nonspecific products). C, 293T cells were transfected with vector control (VC), FLAG-p38, DN-MKK6, or
FLAG-DN-IKKb (FLAG-IKKb SS-AA) by the calcium phosphate transfection protocol. 48 h post-transfection, cells were stimulated with recom-
binant murine IL-1b (5 ng/ml) for 30 min and assayed for p38 phosphorylation status. The arrows indicate proteins detected, FLAG-p38 and
a-tubulin as a loading control and nonspecific products (NS). D, wild type (WT) and IKKa (IKKa2/2) and IKKb (IKKb2/2) null MEFs were plated
in equal cell numbers, stimulated with IL-1b (5 ng/ml) for 30 min, and assayed for p38 phosphorylation status. Bottom panel, blots were stripped
and reprobed for total endogenous p38. Results are representative of three independent experiments.
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pharmacological inhibitor of p38 (SB203580), or, for control
purposes, the pharmacological inhibitor of the MEK pathway
(PD98059) was added for 24 h. Fig. 3A shows that in the
presence of the p38 inhibitor, the ability of Akt to activate
Gal4-p65 was reduced, while the MEK inhibitor showed only a
marginal reduction in Gal4-Luc activity. In addition, Fig. 3B
shows that IL-1b stimulation of 293T cells similarly showed a
reduction in NF-kB transactivation potential in the presence of
SB203580. The SB203580 compound has been shown to inac-
tivate additional MAPK signaling pathways and has been sug-
gested to inhibit Akt kinase activity at high concentrations
(45). The effects of the p38 inhibitor shown in Fig. 3, A and B,
are unlikely to be due to reduced Akt kinase activity or other
nonspecific effects, since the concentration of SB203580 used in
our experiments (600 nM) is considerably lower than reported
concentrations (3–5 mM) affecting Akt or other signaling path-
ways (45). Additionally, analysis of extracts from cells treated
with SB203580 or PD98059 shows that these inhibitors do not
affect M-Akt expression levels as determined by Western blot
(Fig. 3A, bottom panel). Nevertheless, additional experiments
were performed to confirm the results obtained with the
SB203580 compound. Constructs encoding a dominant nega-
tive mutant of p38 (DN p38) were transiently transfected into
NIH 3T3 cells with activated Akt and assayed for 3X-kB Luc
and Gal4-Luc/Gal4-p65 activity. The dominant inhibitory mu-
tant of p38 blocked the ability of Akt to stimulate NF-kB
dependent transcription and showed a similar inhibition on
Gal4-Luc/Gal4-p65 activity corroborating the effects seen with
the SB203580 compound (Fig. 4, A and B). Importantly, these
effects were not due to aberrant expression of M-Akt or p38 as
assayed by Western blot (Fig. 4C). These results taken in whole
demonstrate that IL-1b requires Akt and IKK to stimulate p38
and that p38 activity is required for IL-1b and Akt to activate
the transcription function of NF-kB. Interestingly, the activa-
tion of p38 alone is apparently insufficient for the activation of
p65 transactivation function, since MKK3, an upstream in-
ducer of p38 function, was unable to activate Gal4-p65 (data
not shown).
Akt Utilizes p38 and CBP/p300 for Efficient Stimulation of
the RelA/p65 Subunit of NF-kB—The mechanism of p38-me-
diated NF-kB activation is most likely not directly at the level
of NF-kB, because p38 does not activate RelA/p65 by a direct
phosphorylation event (32). In addition, RelA/p65 does not con-
tain a consensus MAPK/p38 phosphorylation site.2 However,
NF-kB interacts with the basal transcription machinery and
requires co-activators for efficient stimulation of transcrip-
tional activity (46, 47). One co-activator that is essential for
NF-kB-dependent transcription is CBP/p300 (28). Therefore,
we hypothesized that in response to Akt, p38 may utilize CBP/
p300 to stimulate NF-kB transcription. To answer this ques-
tion, constructs encoding activated Akt, CBP, or p300 were
transiently co-transfected into NIH 3T3 cells along with Gal4-
Luc and Gal4-p65. As shown in Fig. 5A, CBP and p300 syner-
gistically activate RelA/p65 in conjunction with activated Akt.
Importantly, these effects were not due to elevated levels of
HA-M-Akt in the transfections (Fig. 5A, bottom panel). Inter-
estingly, as shown in Fig. 5B, the SB203580 compound blocked
this synergy by approximately 2-fold, consistent with the data
presented in Fig. 3A. This effect is specific to p38, since the
2 L. V. Madrid and A. S. Baldwin Jr., unpublished observations.
FIG. 3. Akt requires the p38 MAPK for efficient stimulation of
NF-kB transactivation. A, NIH 3T3 cells were transiently transfected
with plasmids encoding Gal4-Luc and Gal4-p65 (100 ng each) and VC or
M-Akt (2 mg each). 24 h post-transfection, SB203580 (600 nM) and
PD98059 (2 mM) were added for an additional 24 h. B, human 293T cells
were transiently transfected with plasmids encoding Gal4-Luc and
Gal4-p65 (1 mg each). 24 h post-transfection, SB203580 (600 nM) and
PD98059 (2 mM) were pretreated for 90 min followed by human recom-
binant IL-1b (5 ng/ml) or vehicle (NA) for an additional 20 h. Luciferase
levels were assayed, normalized, and expressed as -fold induction over
vector control 6 S.D. of three experiments.
FIG. 4. Dominant negative p38 mutants block Akt-mediated
NF-kB transactivation. A, NIH 3T3 cells were transiently transfected
with plasmids encoding 3X-kB Luc (0.5 mg) or VC or M-Akt (2 mg each).
B, NIH 3T3 cells were transiently transfected with plasmids encoding
Gal4-Luc and Gal4-p65 (100 ng each) and VC, M-Akt, or dominant
negative p38 (DN-p38) (2 mg each). 48 h post-transfection, whole cell
extracts were isolated. Luciferase was normalized to total protein, and
b-galatosidase staining was performed to ensure equal transfection
efficiency and to ensure equal cell viability between conditions. Data is
presented as -fold activation, where the values obtained for the vector
control group were normalized to 1. Results represent the mean 6 S.D.
of three independent experiments. C, whole cell extracts were reana-
lyzed for equivalent protein expression by Western blot. Activated HA-
tagged Akt (HA M-Akt), FLAG-tagged DN p38, and a-tubulin-specific
antibodies were used as described under “Experimental Procedures.”
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MEK inhibitor PD98059 does not appreciably reduce this syn-
ergy (Fig. 5B). Together, these data support the notion that Akt
activates p38 to indirectly stimulate the transactivation do-
main I of the RelA/p65 subunit of NF-kB through a functional
interaction with the co-activator CBP/p300.
DISCUSSION
The results presented here are consistent with the idea that
IL-1b and Akt activate NF-kB by stimulating the transactiva-
tion domain I of RelA/p65. In Fig. 6, we present a model to
explain how Akt transcriptionally activates the RelA/p65 sub-
unit of NF-kB. We propose two mechanisms for Akt-mediated
NF-kB activation: 1) Akt expression alone utilizes IKKb in a
p38-dependent manner, which requires serines 529 and 536 of
RelA/p65 to directly stimulate NF-kB activity, and 2) Akt sig-
naling in response to IL-1 exposure stimulates NF-kB by acti-
vating p38 in a manner dependent on IKKa. It is presently
unclear why different Akt-dependent events differentially tar-
get the two forms of IKK. Additionally, how Akt may activate
p38 is presently unclear, but it may involve utilization of the
p38-activating kinases known as the MKKs, or the activation
of p38 by Akt may involve MKK-independent mechanisms. In
addition, Ras expression or integrin ligation of cells has been
shown to activate p38 by a linear pathway requiring Rac, Pak,
and MKK3 (48, 49). Interestingly, Ras-induced activation of
Pak required Akt kinase activity, indicating that Akt may be
a Pak kinase leading to p38 phosphorylation. However, in a
separate study, IL-1 stimulation of cells activated p38 by a
Ras-dependent, but Rac-independent mechanism, indicating
that IL-1 stimulation may not require the Rac/MKK pathway
(50). Recent data suggest that MKK6 interacts with IKKb,
suggesting that p38 may be activated by the MKK6zIKKb com-
plex (51). However, our results presented here demonstrate
that IKKb is dispensable for the ability of IL-1b to activate p38.
IL-1 signaling is known to involve many pathways in addition
to the described Akt-IKK pathway, and this report highlights
the complexity of IL-1 signaling. This observation and the data
presented in Fig. 2, C and D, suggest that p38 lies downstream
of IKK activity. However, these observations do not rule out the
FIG. 5. Akt and p38 require the co-activator CBP/p300 for effi-
cient stimulation of the RelA/p65 transactivation domain. A,
NIH 3T3 cells were transiently co-transfected with constructs encoding
Gal4-Luc and Gal4-p65 (100 ng of each) and VC, M-Akt, CBP, or p300
(2 mg of each). B, NIH 3T3 cells were transiently transfected with
plasmids encoding Gal4-Luc and Gal4-p65 (100 ng each) and VC, M-
Akt, or CPB (2 mg of each). 24 h post-transfection, SB203580 (600 nM),
PD98059 (2 mM), or Me2SO (DMSO; vehicle control) were added for an
additional 24 h. Luciferase levels were assayed, normalized, and ex-
pressed as -fold induction over vector control 6 S.D. of three
experiments.
FIG. 6. Model: IL-1b/Akt stimulates the transactivation potential
of RelA/p65 by targeting IKK and p38. In this model, we propose that
1) Akt expression alone utilizes IKKb in a p38-dependent manner that
requires serines 529 and 536 of RelA/p65 to directly stimulate NF-kB
activity and 2) Akt signaling in response to IL-1 exposure stimulates
NF-kB by activating p38 in a manner dependent on IKKa.
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possibility that IKK and p38 are on separate but parallel path-
ways for NF-kB activation and that the inhibition of IKK in-
hibits a parallel but not upstream event required for p38 in-
duction. Regulation of p38 activation is complex, and the
mechanisms whereby Akt and IL-1 regulate this kinase require
further investigation.
In contrast to the canonical role of IKKb to induce phospho-
rylation of IkB and to subsequently induce nuclear transloca-
tion of NF-kB, we find that IKKb can also modulate the trans-
activation function of NF-kB in response to Akt. The function of
IKKb in the activation of NF-kB by Akt expression alone is
probably associated with activation of NF-kB transcriptional
function and may not be associated with its well defined role in
transient NF-kB activation. However, we cannot rule out the
possibility that Akt functions to induce nuclear translocation in
response to certain physiological stimuli. Additionally, our
findings provide a function for the direct phosphorylation event
seen on RelA/p65 by IKKb that has been previously reported
(24, 36), and they likely explain, at least partly, previous re-
ports showing that Akt utilizes IKK for activation of NF-kB.
Our findings also demonstrate that p38 is activated by Akt to
utilize the CBP/p300 co-activator for transactivation of NF-kB.
The p38 pathway is well established in stimulating the trans-
activation properties of NF-kB independent of signals that
induce the nuclear accumulation and DNA binding. Our work
suggests that p38 utilizes co-activators to stimulate NF-kB,
and it corroborates previously published reports demonstrating
that p38 modulates NF-kB by an indirect mechanism (32, 42).
Together, these findings represent novel functions associated
with IKKa, IKKb, and p38 in IL-1b- and Akt-mediated NF-kB
activation.
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